The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC).
Juerg Bernhard
No relevant relationships to disclose
Weixiu Luo
No relevant relationships to disclose
Karin Ribi
No relevant relationships to disclose
Marco Colleoni
No relevant relationships to disclose
Harold J. Burstein
No relevant relationships to disclose
Carlo Tondini
No relevant relationships to disclose
Graziella Pinotti
No relevant relationships to disclose
Simon Spazzapan
No relevant relationships to disclose
Thomas Ruhstaller
No relevant relationships to disclose
Fabio Puglisi
No relevant relationships to disclose
Lorenzo Pavesi
No relevant relationships to disclose
Vani Parmar
No relevant relationships to disclose
Meredith M. Regan
No relevant relationships to disclose
Olivia Pagani
No relevant relationships to disclose
Gini F. Fleming
No relevant relationships to disclose
Prudence A. Francis
No relevant relationships to disclose
Alan S. Coates
No relevant relationships to disclose
Richard D. Gelber
No relevant relationships to disclose
Aron Goldhirsch
No relevant relationships to disclose
Barbara Walley
No relevant relationships to disclose